Amino acids in each: BPC-157 is 15, TB-500 is 7. Identity facts, not product claims.
Published BPC-157 and TB-500 researchPlain-English research guideBPC-157 / TB-500
BPC-157 and TB-500 research guide
Everything worth knowing, without the jargon.
This set pairs two separate research peptides - BPC-157 and TB-500 - both studied in tissue-repair research, and both kept separate here. Neither is an approved medicine, and there's no research on combining them.
REV 2026-07 · 7 Aug 20264 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
Studies of the two combined - each is researched on its own, in lab and animal models.
Published researchWhen the BPC-157 story began (a protective substance in gastric juice was described).
Sikiric et al., 1993When the TB-500 story began (the parent protein thymosin beta-4 was sequenced).
Low et al., 1981Why it matters
Two research stories, kept apart.
BPC-157 and TB-500 are offered together because both come up in tissue-repair research - but they're unrelated compounds with separate histories. BPC-157 is based on a partial sequence of a protective protein in gastric juice; TB-500 is a small active piece of the protein thymosin beta-4.
What they share is where the evidence sits: almost entirely in cells and animals, with no completed human trials of either. They don't share a combined research story - there's no published work on using them together, and this set makes no such claim.
How it works
Two compounds, two separate records.
A plain-English look at each pathway, kept at a summary level.
BPC-157, in brief
A 15-amino-acid peptide based on a partial sequence of a gastric-juice protein, studied in rodent and cell models of gut, tendon and blood-vessel repair. See the BPC-157 guide for detail.
TB-500, in brief
A seven-amino-acid fragment of thymosin beta-4 (the actin-binding part), studied - mostly as the full protein - for cell movement and tissue repair. See the TB-500 guide for detail.
No combined claim
There's no published research on combining the two. They're supplied as two separate compounds, each with its own identity and lab report.
Pharmacology at a glance
- Research code
- BPC-157 (GEPPPGKPADDAGLV) + TB-500 (Ac-LKKTETQ)
- Class
- Two separate synthetic research peptides studied in tissue-repair research - supplied together, not as a combined drug.
- Molecule
- BPC-157 is a 15-amino-acid peptide based on a partial sequence of a gastric-juice protein; TB-500 is the seven-amino-acid actin-binding fragment of thymosin beta-4. Two distinct compounds.
- Route studied
- In the animal studies each was given by injection. That's the research record, not use guidance, and it doesn't describe using them together.
- Reported half-life
- BPC-157 had a short half-life (under about 30 minutes) in a rat and dog study; TB-500's is not established in humans.
- Originator
- BPC-157 came from a University of Zagreb group (1990s); the thymosin beta-4 protein behind TB-500 was sequenced in 1981, and the fragment characterised in 2012.
- Approval status
- Neither is an approved medicine anywhere; both are on the World Anti-Doping Agency prohibited list. Preclinical research compounds.
What it has been studied for
Study areas from the published literature.
BPC-157 - tissue & gut repair
Gut, tendon and blood-vessel repair, in rats and cell cultures.
Chang et al., 2011; Hsieh et al., 2017TB-500 - the actin-binding fragment
The part of thymosin beta-4 the fragment copies, and wound-repair work (mostly on the full protein).
Van Troys et al., 1996; Philp et al., 2003Both - preclinical only
Neither has completed human trials; the evidence is lab and animal.
Published researchNo combination research
There's no published study of the two used together.
Published researchThe studies
The evidence, study by study.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
A tendon-repair study on cultured tendon cells and a cut Achilles tendon in rats.
- Studied in
- Cultured rat tendon fibroblasts plus rats.
- Design
- A lab cell study alongside an animal tendon-healing model.
- Measured
- Cell growth and movement in the dish, and tendon healing in the rats.
The tendon cells grew and migrated more, and the rat tendons were reported to heal faster. Animal and cell results - not a claim about people.
DOI 10.1152/japplphysiol.00945.2010An angiogenesis (new-blood-vessel) study in cultured cells and a rat blood-flow model.
- Studied in
- Cultured human vascular cells plus rats.
- Design
- Lab cell experiments plus a rat hind-limb blood-flow model.
- Measured
- New-vessel growth and VEGFR2 signalling.
It linked BPC-157 to more new-vessel growth and VEGFR2 signalling in these models. Cell and animal findings only.
DOI 10.1007/s00109-016-1488-yA lab study that mapped the actin-binding region (residues 17-23) of thymosin beta-4 - the stretch TB-500 copies.
- Studied in
- Lab experiments with thymosin beta-4 and engineered variants.
- Design
- An in-vitro structure-function study.
- Measured
- Which residues were needed to bind actin.
It identified the region that became the TB-500 fragment. It's about the whole protein, not the fragment product.
DOI 10.1002/j.1460-2075.1996.tb00350.xThe closest genuine study of a TB-500-type short fragment: the seven-amino-acid actin-binding peptide tested in mice with slow-healing wounds.
- Studied in
- Mice (diabetic and aged models).
- Design
- An animal wound-healing model comparing the full protein and the short fragment.
- Measured
- How well wounds healed.
The short fragment reproduced much of the full protein's wound-repair effect in these mice - the best direct precedent, but still an animal result.
DOI 10.1046/j.1524-475X.2003.11105.xRisks recorded in studies
The side effects the trials reported.
Human safety isn't established for either
Not establishedNeither BPC-157 nor TB-500 has completed human trials, so their human safety profiles aren't established.
No combined evidence
A key caveatThere's no research on using the two together, so nothing is known about combining them - and this set makes no such claim.
Banned in sport
RegulatoryBoth are on the World Anti-Doping Agency prohibited list, so neither is permitted for athletes.
Not approved medicines
RegulatoryNo medicines regulator has approved either compound for any use. They're supplied here only as research materials.
This section summarizes third-party trial records. It is not a complete safety profile or advice.
Where evidence stops
Groups and questions not established.
- The two combined: there's no published research on using BPC-157 and TB-500 together.
- People: no completed human trials of either compound.
- Long-term safety: not established for either.
- Doses, timing and preparation: not covered here - Form Labs gives no such guidance.
Development and status
Where the research record sits.
The parent protein behind TB-500, thymosin beta-4, is sequenced.
The protective gastric-juice substance behind BPC-157 is described.
Animal and cell studies: BPC-157 for gut/tendon/vessels; the thymosin beta-4 actin region is mapped.
The Ac-LKKTETQ 'TB-500' fragment is characterised.
A first controlled human trial of BPC-157 begins; a TB-500 safety trial is recruiting. Results are pending.
Approval status: Neither is an approved medicine anywhere; both are on the World Anti-Doping Agency prohibited list. Preclinical research compounds.Whatever the molecule’s status elsewhere, what Form Labs supplies is research-use-only reference material - for laboratory work, not for people or animals.
Evidence and limitations
What this means, and what it does not.
Both are preclinical
The evidence for each is in cells and animals, and often - for TB-500 - on the parent protein rather than the fragment. Animal results often don't carry over to people.
There's no combined research
Nothing has been published on using the two together, so any 'stack' idea is not backed by research. This set makes no combined claim.
Neither is settled science
BPC-157's literature leans heavily on one originating group; TB-500's direct fragment evidence is thin. Both are early-stage research areas.
Where Form Labs fits
This guide is a plain-English summary of published research Form Labs did not run. It's not medical advice, not a product claim, and not use guidance. We supply the set strictly as reference material, with batch numbers you can match to the lab reports.
Lab handling
Reference-material handling context.
Research-use boundary
BPC-157 and TB-500 is supplied strictly for laboratory research. It is not for human consumption, veterinary, medical, or cosmetic use, and no directions for use are given.
Storage
Supplied freeze-dried. Keep it at 2-8 C (fridge-cold) and out of light, following the vial label, the matching lab report for the batch, and your lab's own written procedures.
Reconstitution
Reconstitution means mixing the dry powder back into liquid for handling. This guide doesn't set a method - that's down to the receiving lab's written protocol and the batch paperwork.
Stability
How long a freeze-dried peptide stays within spec depends on how it's stored, and is tracked through the batch paperwork. Any working window after it's mixed belongs in the lab's own protocol, not this guide.
Glossary
Plain-English definitions.
- Peptide
- A short chain of amino acids.
- BPC-157
- A synthetic 15-amino-acid peptide based on a protective protein in gastric juice.
- TB-500
- A synthetic seven-amino-acid fragment of the protein thymosin beta-4.
- Thymosin beta-4
- A natural 43-amino-acid protein; TB-500 is a small piece of it.
- Preclinical
- Research in cells and animals, before trials in people.
- In-vivo
- In a living animal.
- Angiogenesis
- The growth of new blood vessels.
- Research use only
- Supplied for laboratory research - not for human or animal use, and not a medicine.
FAQ
Questions answered plainly.
The set is two separate research peptides, each with its own lab report: BPC-157 (a 15-amino-acid peptide, GEPPPGKPADDAGLV) and TB-500 (a seven-amino-acid fragment, Ac-LKKTETQ, of the protein thymosin beta-4). Two different compounds with two different research stories, kept separate.
There's no evidence for that. No published research studies BPC-157 and TB-500 in combination, so nothing is known about using them together. Each is researched on its own, in cells and animals, and this guide makes no combined or synergistic claim.
They aren't, biologically. BPC-157 is based on a partial sequence of a protein in gastric juice; TB-500 is a fragment of a different protein, thymosin beta-4. They share only a research theme - tissue repair - and are grouped as a set for that reason, not because they act alike or together.
Both are preclinical. BPC-157 has a large but single-group-dominated animal literature and no completed human trials. TB-500's own fragment evidence is thin - most of the well-known findings are on its parent protein, thymosin beta-4, not the fragment - and it also has no published human trials. Neither is settled science.
Not in completed, published trials. BPC-157's first controlled human trial (NCT07437547) began in 2026, with results expected around 2027; a TB-500 safety study (NCT07487363) is recruiting with no results. Today's evidence for both is almost entirely from cell and animal research.
BPC-157 is studied - in rats and cell cultures - for gut, tendon and blood-vessel repair (e.g. Chang et al., 2011). TB-500, and more often its parent protein thymosin beta-4, is studied for cell movement and wound repair (e.g. Van Troys et al., 1996; Philp et al., 2003). All preclinical.
Neither is approved as a medicine by any regulator (the TGA, FDA or EMA), and both are on the World Anti-Doping Agency prohibited list for athletes. Form Labs supplies the set strictly as laboratory research materials, not for human or veterinary use.
Form Labs supplies peptides strictly as laboratory research materials. This guide is a plain-English summary of published research Form Labs did not run - not medical advice, not a product claim, and not guidance for any human or veterinary use.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
BPC-157 - foundational gastric-juice paper. Sikiric P, et al. Journal de Physiologie (Paris), 1993; 87(5): 313-327.
DOIBPC-157 - rat and cell tendon-healing study. Chang C-H, et al. Journal of Applied Physiology, 2011; 110(3): 774-780.
DOIBPC-157 - cell and rat angiogenesis study. Hsieh M-J, et al. Journal of Molecular Medicine, 2017; 95(3): 323-333.
DOITB-500 - mapping the actin-binding region of thymosin beta-4. Van Troys M, et al. The EMBO Journal, 1996; 15(2): 201-210.
DOITB-500 - mouse study of the short actin-binding fragment in wound healing. Philp D, et al. Wound Repair and Regeneration, 2003; 11(1): 19-24.
DOITB-500 - synthesis and characterisation of the Ac-LKKTETQ fragment. Esposito S, et al. Drug Testing and Analysis, 2012; 4(9): 733-738.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
- Who writes them
- These guides are written and maintained in-house by the Form Laboratories research team. They are not authored by a named clinician, and nothing in them is medical advice. Where a guide is short, that is because the published research is thin - we would rather say so than fill the space.
- What they are built from
- Each guide summarises published, peer-reviewed literature. Every study we describe is listed in full at the bottom of the page with a link to the original paper, so you can open it and check what it actually says. Form Laboratories did not run any of the cited studies.
- What they deliberately leave out
- These guides describe how the biology works and what the published research measured. They do not contain dosing, preparation, reconstitution or administration instructions, and they make no claim about what any compound would do for a person. Everything we supply is research-use-only reference material.
- How we handle uncertainty
- Where the evidence is limited to cell cultures or animals, we say so in the study entry rather than implying a human result. Where a compound has no completed human trial, the guide states that plainly.
The product
Form Laboratories - BPC-157 & TB-500
Ready to see BPC-157 & TB-500?
- Independently tested - purity printed on the lab report.
- A batch number on every vial, matched to its report.
- Ships from Perth via Australia Post in plain packaging.
From
$119.00 AUD
10 mg - 98% - 2-8 C
Reference material for laboratory research only.
Build your stack
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View BPC-157 & TB-500 - from $119.00 AUD